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Abstract
Background: Vaspin and omentin are recently described molecules that belong to the adipokine family and seem
to be related to metabolic risk factors. The objectives of this study were twofold: to evaluate vaspin and omentin
circulating levels and mRNA expression in subcutaneous and visceral adipose tissues in non-diabetic morbidly
obese women; and to assess the relationship of vaspin and omentin with anthropometric and metabolic
parameters, and other adipo/cytokines.
Design: We analysed vaspin and omentin circulating levels in 71 women of European descent (40 morbidly obese
[BMI ≥ 40 kg/m
2] and 31 lean [BMI ≤ 25]). We assessed vaspin and omentin gene expression in paired samples of
visceral and subcutaneous abdominal adipose tissue from 46 women: 40 morbidly obese and 6 lean. We
determined serum vaspin and plasma omentin levels with an Enzyme-Linked Immunosorbent Assay and adipose
tissue mRNA expression by real time RT-PCR.
Results: Serum vaspin levels in the morbidly obese were not significantly different from those in controls. They
correlated inversely with levels of lipocalin 2 and interleukin 6. Vaspin mRNA expression was significantly higher in
the morbidly obese, in both subcutaneous and visceral adipose tissue.
Plasma omentin levels were significantly lower in the morbidly obese and they correlated inversely with glucidic
metabolism parameters. Omentin circulating levels, then, correlated inversely with the metabolic syndrome (MS).
Omentin expression in visceral adipose tissue was significantly lower in morbidly obese women than in controls.
Conclusions: The present study indicates that vaspin may have a compensatory role in the underlying
inflammation of obesity. Decreased omentin circulating levels have a close association with MS in morbidly obese
women.
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Background
The incidence of obesity is rising rapidly in industria-
lized and developing countries. Increased abdominal
visceral fat is associated with insulin resistance, type 2
diabetes, and coronary heart disease [1]. Reduction of
visceral fat mass by omentectomy has significant posi-
tive and long-term effects on glucose metabolism,
insulin sensitivity, and metabolic profiles in obese sub-
jects [2]. In the last decade, numerous studies have
revealed that adipose tissue secretes a variety of bioac-
tive substances that could explain the epidemiologic
relationship between visceral fat mass and increased
metabolic risk. These substances, termed adipokines,
include leptin [3], adiponectin [4], resistin [5], lipocalin
2(LCN2) [6], fatty acid binding proteins (AFABP) [7],
plasminogen activator inhibitor-1 [8], interleukin 6 (IL
6) [9], and various growth factors. They are considered
to play an important role in interactions between a
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central and peripheral nervous systems [10]. In obese
subjects, expression, synthesis and release of pro-
inflammatory cytokines (tumor necrosis factor-alpha
[TNF-a], IL 6) and adipokines (leptin, resistin) is
enhanced but anti-inflammatory adipokines such as
adiponectin are decreased [11].
Recently, vaspin (visceral adipose tissue-derived ser-
ine protease inhibitor) was identified as a member of
t h es e r i n ep r o t e a s ei n h i b i t o rf a m i l y .V a s p i nc D N A
was isolated from visceral white adipose tissues
(WAT) of Otsuka Long-Evans Tokushima Fatty
(OLETF) rats, an animal model of abdominal obesity
with type 2 diabetes [12]. Vaspin is highly expressed
in rat adipocytes from visceral WAT at the age when
obesity and insulin plasma concentrations reach a
peak [13]. Vaspin improves insulin sensitivity in mice
[13]. However, in humans the effect of vaspin on
insulin sensitivity is uncertain and the correlation
between vaspin and body mass index (BMI) is also
unclear [14,15].
Omentin 1 was identified as a novel adipokine predo-
minantly secreted by visceral stromal vascular cells but
not adipocytes [16,17]. Furthermore, in vitro experi-
ments revealed that treatment with recombinant omen-
tin-1 enhances insulin-mediated glucose uptake in
human subcutaneous and omental adipocytes, while
increasing Akt/PKB phosphorylation [17]. In cultured
adipocytes, omentin 1 production is decreased by D-glu-
cose and insulin [18,19].
Nevertheless, in studies involving humans, the plasma
concentration of omentin-1-the major circulating iso-
form in human plasma-is decreased in patients with
type 1 diabetes mellitus [18,19] and not affected by glu-
cose ingestion [20]. In addition, omentin plasma levels
and omentin gene expression in visceral adipose tissue
are decreased in obesity [19].
Although some studies have focused on the abnormal
levels of vaspin and omentin in metabolic syndrome
patients and mRNA expression, particularly with refer-
ence to BMI and markers of insulin sensitivity, the regu-
lation of these molecules and their relationship with
other adipokines in morbidly obese patients has not
been specifically studied.
Our objective in this study was to measure the circu-
lating levels of vaspin and omentin and mRNA expres-
sion in subcutaneous and visceral adipose tissue in
morbidly obese women and make a comparison with
age-matched control women (we studied only women to
avoid sex differences). We also assessed the relationship
between these two adipokines and biochemical markers
of metabolic syndrome, levels of other adipokines, and
pro-inflammatory cytokines.
Methods
Subjects
The study was approved by the institutional review
board. All participants gave written informed consent
for participation in medical research. We analyzed the
circulating levels of vaspin and omentin in 71 Spanish
women of European descent: 31 lean (BMI < 25 Kg/m2)
and 40 morbidly obese (BMI > 40). We also analyzed
vaspin and omentin gene expression in paired samples
of subcutaneous and visceral adipose tissue from 46
patients: 6 lean (BMI < 25 Kg/m2) and 40 morbidly
o b e s e( B MI>4 0 ) .A d i p o s et i s s u es a m p l e sw e r e
obtained from morbidly obese women and from control
women who underwent bariatric surgery by laparoscopic
gastric by-pass and elective surgery, respectively. Subcu-
taneous adipose tissue biopsies were taken from the
right hypocondrion region and visceral adipose tissue
biopsies were taken from the greater epiploon region.
For each type of surgery, samples were obtained by the
same specialist. Morbidly obese women and controls
were age matched. The weight of all subjects was stable
for at least three months before surgery. Those patients
who had an acute illness, acute or chronic inflammatory
or infective diseases, or an end-stage malignant disease,
were excluded from. Liver and renal diseases were speci-
fically excluded by biochemical work-up. Control or
morbidly obese patients diagnosed as type 2 diabetes
mellitus or receiving hypolipemiant treatment were also
excluded from the study.
Anthropometric Measurements
BMI was calculated as weight divided by height squared
(kg/m
2) (according to the criteria of the World Health
Organization [21]. Waist circumference (WC) was mea-
sured at the height of the iliac crest.
Diagnosis of Metabolic Syndrome
Morbidly obese women were further subclassified
according to the presence or absence of the metabolic
syndrome (MS). The MS and metabolic risks are defined
according to the US National Cholesterol Education
Program Adult Treatment Panel III guidelines and mod-
ified as recommended in the latest American Heart
Association/National Heart, Lung, and Blood Institute
Scientific Statement [22] by adopting a lower cutoff for
fasting glucose (5.6 mmol/L). The MS was defined as
having 3 of the following metabolic risk factors: (1) cen-
tral obesity (waist circumference 88 cm in women), (2)
hypertriglyceridemia (fasting triglycerides 1.69 mmol/L
(150 mg/dL)), (3) low HDL cholesterol (fasting HDL
<1.29 mmol/L (50 mg/dl) in women), (4) glucose intol-
erance (fasting glucose 5.6 mmol/L (100 mg/dL)), and
(5) hypertension (sitting blood pressure 130/85 mm Hg
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for at least 10 minutes or on regular antihypertensive
medications).
Analytical Methods
Basal, fasting blood samples were taken after an over-
night fast to determine glucose, insulin, and standard
laboratory parameters. Plasma and serum samples were
stored at -80°C until analytical measurements were per-
formed, except for glucose, which was determined
immediately after blood was drawn.
Fasting plasma glucose and lipid profile (triglycerides,
total cholesterol, and high-density lipoprotein choles-
terol) were measured using the usual enzymatic meth-
ods in an ADVIA Centaur auto analyzer. Low-density
lipoprotein cholesterol was calculated as the difference
between total cholesterol, HDL, and triglyceride con-
tent/5 if it was <400 mg/dL. Plasma insulin concentra-
tion was measured by commercial chemiluminescence
assay for ADVIA Centaur (Siemens Medical Solutions S.
L., Barcelona, Spain) according to the manufacturer’s
instructions. The homeostasis model assessment of insu-
lin resistance (HOMA2-IR) was completed using the
HOMA Calculator version 2.2.2 (http://www.dtu.ox.ac.
uk accessed May 2010). Glycosylated hemoglobin
(HbA1c) was measured by a chromatographic method
(Glico Hb Quick Column Procedure, Helena Labora-
tories, Beaumont, TX).
Circulating levels of TNF-RI, TNF-RII (Biosource
Europe S.A., Nivelles, Belgium), IL 6 (Quantikine, R&D
Systems, Minneapolis, USA), adiponectin, HMW adi-
ponectin (Linco Research, Inc., St. Charles, USA),
resistin (Biovendor, Modrice, Czech Republic), leptin
(Biovendor, Modrice, Czech Republic), RBP4, lipocalin
2 (Biovendor, Modrice, Czech Republic), serum vaspin
(Adipogen, Seoul, South Korea) and plasma omentin
(Apotech, Axxora, Nottingham, UK) were measured in
duplicate using enzyme-linked immunosorbent assays
(ELISA) following the manufacturer’si n s t r u c t i o n s .
TNF-RI assay sensitivity was 50 pg/mL and the inter-
assay and intra-assay coefficients of variation were less
than 5.7 and 1.7%, respectively. TNF-RII assay sensitiv-
ity was 0.1 ng/mL and inter-assay and intra-assay coef-
ficients of variation were less than 3.2 and 3.3%,
respectively. IL 6 assay sensitivity was 0.039 pg/mL
and inter-assay and intra-assay coefficients of variation
were less than 9.6 and 6.9%, respectively. Adiponectin
assay sensitivity was 0.78 ng/mL and inter-assay and
intra-assay coefficients of variation were less than 8.4
and 7.4%, respectively. HMW adiponectin assay sensi-
tivity was 0.5 ng/mL and inter-assay and intra-assay
coefficients of variation were less than 3.8 and 2.6%,
respectively. Resistin assay sensitivity was 33 pg/mL
and inter-assay and intra-assay coefficients of variation
were less than 6.9 and 3.4%, respectively. Leptin assay
sensitivity was 0.2 ng/mL and inter-assay and intra-
assay coefficients of variation were less than 7.6 and
4.4%, respectively. RBP4 assay sensitivity was 0.02 g/L
and inter-assay and intra-assay coefficients of variation
were less than 1.1 and 2.2%, respectively. LCN 2 assay
sensitivity was 0.01 ng/mL and inter-assay and intra-
assay coefficients of variation were less than 5.6 and
4.4%, respectively. Vaspin assay sensitivity was 12 pg/
mL and inter-assay and intra-assay coefficients of var-
iation were <6% and <4%. Omentin assay sensitivity
was 0.4 ng/mL and inter-assay and intra-assay coeffi-
cients of variation were less than 6 and 2.7%,
respectively.
Analysis of Human Vaspin and Omentin Gene Expression
Total RNA was isolated from adipose tissues with the
RNeasy mini kit (Qiagen) according to the manufac-
turer’s protocol and digested with DNase I (RNase-Free
DNase set, Qiagen). RNA quality was evaluated by mea-
suring the 260/280 nm absorbance ratio (≥1.8) and by
electrophoresis. First-strand cDNA was synthesized
using an equal amount of total RNA with the High
Capacity RNA-to-cDNA Kit (Applied Biosystems). Real-
time quantitative PCR was performed in a final volume
of 20 μL, which contained 10 ng of reverse-transcribed
cDNA, 10 μL of 2X Taq Man Fast Universal PCR Mas-
ter Mix (Applied Biosystems) and 1 μL Taq Man Assay
predesigned by Applied Biosystems
® for the detection of
vaspin, omentin, and GAPDH, used as a housekeeping
gene. All reactions were performed in triplicate and
were carried out in 96-well plates by using the 7900HT
Fast Real-Time PCR systems (Applied Biosystems).
Statistical Analysis
All the values reported are expressed as mean ± SEM
(standard error of the mean) and were analyzed using
the statistical package SPSS/PC+ for Windows (v.15.0
Chicago, Illinois, USA). Differences between groups
were calculated using either Student’s t test or the One-
way ANOVA analysis. The strength of association
between variables was calculated using Pearson’s
method for parametric variables and the Spearman Rho
correlation test for non-parametric contrasts. Multiple
linear regression analysis with backward variable selec-
tion was performed to identify independent predictors
of HOMA2-IR. The validity of the regression model and
its assumptions was assessed with the plot of residuals
vs. predicted values. Data were normally distributed.
Logistic regression analysis was performed to identify
independent predictors of the metabolic syndrome. Vas-
pin and omentin circulating levels were age and BMI
adjusted in some analyses. P values < 0.05 were consid-
ered to be statistically significant.
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Population studied
The baseline patient characteristics given in Table 1
show the mean and SEM of the variables of interest.
Patients were separated into control subjects (BMI < 25
kg/m
2) ,a n dm o r b i ds u b j e c t s( B M I>4 0k g / m
2). The
two groups were well matched for age.
Biochemical analyses indicated that obese women had
significantly higher levels of glucose, insulin, HOMA2-
IR and HbA1c than the control group. Blood pressure
was also increased in the morbidly obese women. The
lipidemic profile differed significantly between groups.
Obese patients showed higher triglyceride levels and
lower HDL cholesterol.
Serum vaspin
Mean ± SD serum vaspin was 0.87 ± 0.96 μg/liter in the
morbidly obese women and not significantly different
from the values of the control group (1.66 ± 2.09 μg/
liter) (Figure 1).
Serum vaspin concentrations did not correlate with
metabolic variables (Table 2) and inversely correlated
with levels of LCN2, leptin and IL 6 (Table 3).
We investigated the relationship between vaspin circu-
lating levels and the presence of the MS but we found
no correlation (Table 4). As expected, the MS correlated
with the BMI, WC, HOMA2-IR, fasting glucose, blood
pressure, HDL cholesterol and triglycerides.
Subcutaneous and visceral vaspin mRNA expression
Vaspin mRNA expression was significantly higher in
morbidly obese women than in controls, in both SAT
and VAT (Figure 2). We found no differences between
visceral and subcutaneous vaspin expression in the adi-
pose tissues of the obese group (p = 0.192) and the con-
trol group (p = 0.934) (Figure 2).
S A Ta n dV A Tv a s p i nm R N Ae x p r e s s i o nd i dn o tc o r -
relate with obesity, glucose metabolism, insulin resis-
tance parameters, blood pressure, other adipokines
studied or inflammatory parameters (data not shown).
Plasma omentin-1
Mean ± SD plasma omentin was 1.97 ± 2.15 ng/mL in
the morbidly obese group and significantly different from
that of the control group (5.27 ± 5.33 ng/mL) (Figure 1).
Plasma omentin levels inversely correlated with fasting
glucose and HOMA2-IR (Table 2) and did not correlate
with the adipokines or cytokines studied (Table 3).
When we investigated the relationship between omentin
circulating levels and the presence of the MS, we found
that omentin correlated negatively with the MS
(Table 4). After adjustment for age and BMI, we sub-
classified the subjects in three tertiles in accordance
with their omentin levels: tertile 1 (>4.33 ng/ml); tertile
2 (4.33-2.30 ng/ml); tertile 3 (<2.30 ng/ml). In a logistic
regression analysis, the lowest omentin levels (tertile 2
and 3) were associated with the presence of MS while
the highest tertile (tertile 1) was not (Table 5).
Visceral and subcutaneous omentin expression
Omentin mRNA expression in SAT was similar in mor-
bidly obese women and controls. However, omentin
expression in VAT was significantly lower in morbidly
obese women than in controls (Figure 2). When com-
paring both adipose tissues, we found that omentin
expression was higher in VAT than in SAT in both the
obese group (p = 0.009) and the control group (p =
0.034) (Figure 2).
SAT and VAT omentin mRNA expression did not
correlate with obesity, glucose metabolism or insulin
resistance parameters. Neither was there any correlation
with lipid metabolism, blood pressure or the other adi-
pokines and cytokines studied (data not shown).
Discussion
It has been reported that abnormalities in the circulating
levels of vaspin and omentin and the gene expression of
both factors are related to BMI and markers of insulin
sensitivity in metabolic syndrome patients, although to
date, the findings of various authors are confusing. Our
objective in this study was to measure vaspin and omen-
tin circulating levels and mRNA expression in subcuta-
neous and visceral adipose tissue in morbidly obese
women and to compare them to age-matched controls.
We also assessed the relationship between these two
adipokines and biochemical markers of metabolic syn-
drome and other adipo/cytokines.
Table 1 Baseline characteristics, anthropometric
measurements, and metabolic analysis of the population
studied
CONTROL
(n = 31)
MORBID OBESE
(n = 40)
p-value
BMI (Kg/m
2) 23.21 ± 0.46 48.22 ± 1.07 <0.001
WC (cm) 80.40 ± 2.16 134.00 ± 3.10 <0.001
AGE (years) 43.53 ± 3.08 46.37 ± 1.54 0.414
GLUCOSE (mg/dL) 94.06 ± 2.53 117.70 ± 4.25 0.001
INSULIN (mU/L) 8.25 ± 1.32 22.69 ± 3.94 0.001
HOMA2-IR 1.11 ± 0.18 2.60 ± 0.24 <0.001
HbA1c (%) 4.55 ± 0.07 5.63 ± 0.29 0.001
HDL-C (mg/dL) 59.83 ± 2.87 40.97 ± 1.33 <0.001
TRIGLYCERIDES (mg/dL) 95.13 ± 9.06 183.52 ± 11.88 <0.001
SBP (mm Hg) 120.91 ± 4.22 134.99 ± 4.07 0.020
DBP (mm Hg) 70.04 ± 1.96 76.70 ± 2.80 0.056
BMI: body mass index, WC: waist circumference, HOMA2-IR: homeostatic
model assessment method insulin resistance, HDL-C: high density lipoprotein
cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure. Data
are the mean ± SEM. * indicates significant differences vs. control group
(p < 0.05).
Auguet et al. BMC Medical Genetics 2011, 12:60
http://www.biomedcentral.com/1471-2350/12/60
Page 4 of 8In the current study, we demonstrate that serum vas-
pin levels are not increased in morbidly obese women
and that vaspin levels do not correlate with BMI, mar-
kers of glucose or lipid metabolism.
In studies involving humans, and as has been men-
tioned in the introduction, how vaspin serum levels cor-
relate with BMI, markers of insulin sensitivity and
glucose metabolism is unclear. Youn et al. have reported
that elevated vaspin serum concentrations correlated
with obesity and impaired insulin sensitivity, although
not in patients with type 2 diabetes [14]. In obese chil-
dren, Lee et al. have observed a negative correlation
between vaspin concentration and HOMA-IR [23].
However, in agreement with our results, von Loeffelholz
et al. have shown that there is no association between
serum vaspin and HOMA-IR in nondiabetic humans
[24]. Seeger et al. have also reported that circulating vas-
pin is not independently associated with markers of glu-
cose metabolism [15], and Briana et al. have shown that
vaspin concentrations do not correlate with insulin
levels in maternal, fetal and neonatal samples [25], as
occurs in our population.
To our knowledge, this is the first time that the rela-
tion between vaspin levels and other adipo/cytokines in
the circulation has been studied.
In our study, serum vaspin levels correlate inversely
with levels of LCN2 and IL 6. It has been reported that
LCN2 is an adipokine that seems to be an independent
risk factor for hyperglycemia and insulin resistance in
humans. It has also been related to inflammation [26].
IL 6 is a known proinflammatory cytokine that also
increased in obesity [9]. Taken together, these findings
might suggest that vaspin has an anti-inflammatory
profile.
On the other hand, vaspin mRNA expression is signif-
icantly higher in our morbidly obese cohort in SAT and
VAT. Kloting et al. have reported that vaspin expression
was not detectable in lean subjects but that it was pre-
sent in both the SAT and VAT of obese patients. Its
levels were significantly correlated with parameters of
obesity, insulin resistance and impaired glucose
Figure 1 Vaspin and omentin concentrations in control women and morbidly obese women. * Indicates statistically significant differences
between groups (p < 0.05).
Table 2 Correlation of vaspin and omentin levels with
metabolic variables
Circulating levels VASPIN OMENTIN
Variables r p-value r p-value
BMI (kg/m
2) -0.181 0.134 -0.212 0.096
WC (cm) -0.448 0.007 -0.332 0.078
Glucose (mg/dL) -0.002 0.989 -0.276 0.029
Insulin (mU/L) -0.015 0.903 -0.252 0.054
HOMA2-IR 0.004 0.976 -0.274 0.037
HbA1c (%) -0.181 0.218 0.011 0.943
HDL-C (mg/dL) 0.166 0.183 -0.178 0.182
Triglycerides (mg/dL) -0.218 0.072 -0.101 0.433
SBP (mm Hg) -0.002 0.986 -0.179 0.201
DBP (mm Hg) -0.019 0.887 -0.072 0.608
BMI: body mass index, WC: waist circumference, HOMA2-IR, homeostatic
model assessment method insulin resistance; HDL-C: high density lipoprotein
cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure. Bolded
p-values indicate statistically significant correlations (p < 0.05).
Table 3 Correlation of vaspin and omentin levels with
circulating adipo/cytokine levels
Circulating levels VASPIN OMENTIN
Variables r p-value r p-value
HMW adiponectin (μg/L) 0.178 0.173 0.078 0.557
Adiponectin (μg/L) 0.145 0.250 0.103 0.431
Resistin (μg/L) -0.178 0.157 -0.150 0.236
LCN2 (μg/L) -0.336 0.016 0.088 0.559
IL6 (ng/L) -0.290 0.029 0.033 0.812
RBP4 (mg/dL) 0.015 0.915 0.013 0.931
TNFRI (μg/L) -0.241 0.057 0.004 0.976
TNFRII (μg/L) -0.051 0.689 0.036 0.787
Leptin (μg/L) -0.290 0.041 0.195 0.199
HMW adiponectin: high molecular weight adiponectin, LCN2: lipocalin 2, IL6:
interleukin 6, RBP4: retinol binding protein 4, TNFRI: tumor necrosis factor
receptor I, TNFRII: tumor necrosis factor receptor II. Bolded p-values indicate
statistically significant correlations (p < 0.05).
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port their findings.
In untreated OLETF rats, vaspin expression and its
serum levels decreased as diabetes worsened and body
weight fell. The expression and serum levels were normal-
ized by treatment with insulin or pioglitazone, suggesting
that vaspin exerts a defensive action against insulin resis-
tance. On the other hand, the administration of recombi-
nant human vaspin improved insulin sensitivity and
glucose tolerance, and reverses the expression of those
genes that can promote insulin resistance such as leptin,
resistin and TNF-a, in diet-induced obese mice [13].
To sum up, in our study serum vaspin levels are
inversely related to IL 6. SAT and VAT vaspin expres-
sion is significantly higher in morbidly obese women.
In addition, as mentioned above, the literature confirms
that vaspin has an insulin-sensitizing effect. In conjunc-
tion with our results, then, this suggests that vaspin has
a compensatory role in the inflammatory complications
of obesity.
The second important finding of our study is that
plasma omentin levels are significantly lower in the
morbidly obese and that these levels inversely correlate
with glucidic metabolism parameters, in accordance
with the findings of de Souza et al. [19] and Yang et al.
[17]. In the same context, we found a negative correla-
tion with systolic blood pressure.
We also demonstrate that patients with omentin levels
in the lowest tertile were 90 times more likely to have
the MS than those in the highest tertile, after adjust-
ment for age and BMI. Moreover, women with omentin
levels in the second tertile were 25 times more likely to
have the MS.
Omentin expression in visceral adipose tissue is sig-
nificantly lower in the morbidly obese women in our
study in agreement with the results of Souza et al [19].
Also, Cai et al. demonstrate that omentin mRNA
expression decreases in overweight/obese individuals
and decreases further when overweight/obesity is com-
bined with type 2 diabetes. Thus, omentin expression
is negatively correlated with fasting insulin, HOMA-IR
and BMI [28].
The major limitation of the present study is the rela-
tively small number of subjects in the sample. Although
our specific cohort of non-diabetic morbidly obese
women showed a clear relationship between the MS
and omentin levels without the interference of con-
founding factors, these results are not extrapolable to
other obesity groups or men. Secondly, due to the diffi-
culty of obtaining tissue samples, the expression results
Table 4 Correlations between the number of diagnostic
criteria of metabolic syndrome met by the patients
Number of criteria of Metabolic syndrome
Variables r p-value
VASPIN (μg/L) -0.209 0.083
OMENTIN (μg/L) -0.264 0.045
BMI (kg/m
2) 0.737 <0.0001
WC (cm) 0.783 <0.0001
HOMA2-IR 0.589 <0.0001
Glucose (mg/dL) 0.710 <0.0001
SBP (mm Hg) 0.636 <0.0001
DBP (mm Hg) 0.250 0.006
HDL-C (mg/dL) -0.750 <0.0001
Triglycerides (mg/dL) 0.704 <0.0001
Vaspin and omentin circulating levels and different parameters.
BMI: body mass index, WC: waist circumference, HOMA2-IR: homeostatic
model assessment method insulin resistance, SBP: systolic blood pressure,
DBP: diastolic blood pressure.
Bolded p-values indicate statistically significant Spearman’s correlations (p <
0.05).
Figure 2 mRNA vaspin and omentin expression in control group (C) (n = 6) and morbidly obese women (MO) (n = 40).*i n d i c a t e s
statistically significant differences between control and morbidly obese subjects (p < 0.05).
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Another limitation of the study is that it is cross-sec-
tional. We could not prove a causal link between the
levels of omentin and the development of MS or the
levels of vaspin and anti-inflammatory action. Further
prospective studies are required to explain these
phenomena.
Conclusion
To sum up, our data suggest that vaspin is likely to have
anti-inflammatory/protective action in morbid obesity.
Also, decreased omentin levels have a close association
with MS in women with morbid obesity. Future studies
should also include parameters for weight loss and exer-
cise to observe their effect on vaspin and omentin levels.
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